Lubiprostone: A new drug for the treatment of chronic idiopathic constipation

Reviews in Gastroenterological Disorders

Volumn 7, Issue 4, 2007, Pages 214-222

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Constipation; Irritable bowel syndrome; Lubiprostone

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTACID AGENT; ANTIDIARRHEAL AGENT; ANTIPARKINSON AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; IRON; LAXATIVE; LUBIPROSTONE; MACROGOL; MISOPROSTOL; MORPHINE; MOXIFLOXACIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PROSTAGLANDIN E1; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AREA UNDER THE CURVE; CAUSAL ATTRIBUTION; CHRONIC IDIOPATHIC CONSTIPATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ELECTROLYTE BLOOD LEVEL; FATIGUE; FLATULENCE; HEADACHE; HEART INFARCTION; HUMAN; IRRITABLE COLON; LOOSE FECES; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; STOMACH DISCOMFORT; STROKE; THORAX PAIN; UNSTABLE ANGINA PECTORIS; VOMITING; XEROSTOMIA;

ALPROSTADIL; ANIMALS; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; DRUG EVALUATION; FATTY ACIDS; HUMANS; TREATMENT OUTCOME;

EID: 37849038254     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. American Gastroenterological Association. AGA technical review on constipation. Gastroenterology. 2000;119:1766-1778.
2. American Gastroenterological Association. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1766.
3. Hsieh C. Treatment of constipation in older adults. Am Fam Physician. 2005;72:2277-2284.
4. Johnson DA. Treating chronic constipation: how should we interpret the recommendations? Clin Drug Invest. 2006;26:547-557.
5. Novartis Pharmaceuticals. Zelnorm (tegaserod maleate). East Hanover, NJ: Novartis Pharmaceuticals; July 2007. Available at: www.zelnorm.com. Accessed September 11, 2007.
6. Sucampo Pharmaceuticals. Amitiza (lubiprostone) soft gelatin capsules [package insert]. Bethesda, MD: Sucampo Pharmaceuticals; February 2006.
7. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287:C1173-C1183.
8. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942-G947.
9. Perentesis GP, Crawford DF, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle [abstract 900]. Am J Gastroenterol. 2005;100(9 suppl):S330.
10. Moeser A, Engelke K, Perentesis GP, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the Clc-2 chloride channel, Spi-0211 [abstract]. Gastroenterology. 2005;128(4 suppl 2):A539.
11. - currents in caco-2 cells from the apical side [abstract T1887]. Presented at Digestive Disease Week 2007; May 19-24, 2007; Washington, DC.
12. Eaton DC, Bao H, Liu L, Ueno R. Lubiprostone activates single chloride channels in the apical membrane of A6 epithelial cells [abstract T1875]. Presented at Digestive Disease Week 2007; May 19-24, 2007; Washington, DC.
13. Fei G, Liu S, Wang G, et al. Stimulation of mucosal secretion by lubiprostone in guinea-pig small intestine and colon [abstract W1206]. Presented at Digestive Disease Week 2007; May 19-24, 2007; Washington, DC.
14. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41:345-351.
15. Chen TY. Structure and function of CLC channels. Annu Rev Physiol. 2005;67:809-839.
16. Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol. 2007;292:G647-G656.
17. Crawford DF, Perentesis GP, Engelke KJ, et al. Pharmacokinetic profile on lubiprostone, a selective GI chloride channel activator, after a single oral dose in multiple animal species [abstract 901]. Am J Gastroenterol. 2005;100(9 suppl):S330.
18. Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation [abstract 1511]. Gastroenterology. 2002;122:A315.
19. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351-1361.
20. Johanson JF, Gargano MA, Holland PC, et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [abstract]. Gastroenterology. 2003;124:A48.
21. Johanson JR, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week phase III study [abstract 884]. Am J Gastroenterol. 2005;100(9 suppl):S324-S325.
22. Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy [abstract 896]. Am J Gastroenterol. 2005;100(9 suppl):S328-S329.
23. Johanson JF, Gargano MA, Holland PC, et al. Phase III patient assessments of the effects of lubiprostone, a chloride channel-2 (ClC-2) activator, for the treatment of constipation [abstract 899]. Am J Gastroenterol. 2005;100(9 suppl): S329-S330.
24. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs non-elderly subjects [abstract] Gastroenterology. 2006;130:A189.
25. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs female subjects [abstract]. Gastroenterology. 2006;130:A322.
26. Johanson J, Wahle A, Ueno R. Efficacy and safety of lubiprostone in a subgroup of constipation patients diagnosed with irritable bowel syndrome with constipation (IBS-C) [abstract]. Am J Gastroenterol. 2006;101(9 suppl):S491.
27. Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [abstract]. Gastroenterology. 2004;128:A100.
28. Johanson JF, Gargano MA, Holland PC, et al. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation [abstract 903]. Am J Gastroenterol. 2005;100(9 suppl):S331.
29. Johanson J, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation [abstract]. Gastroenterology. 2006;130:A317.
30. Ueno R, Wahle A, Panas R, et al. Evaluation of safety and efficacy in a twelve-month study of lubiprostone for the treatment of chronic idiopathic constipation [abstract]. Am J Gastroenterol. 2006;101(9 suppl):S491.
31. Ueno R, Panas R, Wahle A, et al. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects [abstract]. Gastroenterology. 2006;130:A188.
32. Johanson J, Panas R, Holland PC, Ueno R. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS) [abstract]. Gastroenterology. 2006;130:A25.
33. Drossman DA, Chey W, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials [abstract]. Gastroenterology. 2007;132:2586.
34. Engelke K, Harris S, Roerig B, Ueno R. Effect of lubiprostone, a novel type-2 chloride channel (ClC-2) activator, in pregnant Rhesus monkeys [abstract T1683]. Presented at Digestive Disease Week 2007; May 19-24, 2007; Washington, DC.
35. Ueno R, Wahle A, Rivera E. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone [abstract]. Am J Gastroenterol. 2006;101(9 suppl):S489.
36. Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation [abstract]. Gastroenterology. 2007;132:A191-A192.
37. Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiographic results [abstract]. Gastroenterology. 2007;132:A325.
38. Ueno R, Osama H, Engelke KJ. Effects of lubiprostone on morphine-induced constipation and analgesia [abstract]. Gastroenterology. 2006;130:A373.
39. PR Newswire. FDA accepts Sucampo's sNDA for lubiprostone (8 μg) for the treatment of irritable bowel syndrome with constipation (IBS-C). Available at: www.prnewswire.com (key word: lubiprostone). Accessed September 17, 2007.